Many cancer drugs remain unproven 5 years after accelerated approval, says Study
Advertisement
The promise of early access to potentially life-saving drugs through the US Food and Drug Administration's accelerated approval program often comes with high hopes for patients battling debilitating or fatal diseases. However, a recent study sheds light on the reality that many of these drugs fail to demonstrate significant benefits within a reasonable timeframe.
Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania, underscores the urgency of obtaining definitive answers about the efficacy of accelerated approval drugs within five years. "Thousands of people are getting those drugs. That seems a mistake if we don't know whether they work or not," he emphasizes.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.